Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01350921 · ClinicalTrials.gov registry record · Phase 1

Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT01350921 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 22 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01350921, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

Study evaluates the drug-drug interaction between Ticagrelor and Venlafaxine when taken together in healthy volunteers

Interventions

  • DRUG Ticagrelor
  • DRUG Venlaflaxin

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2011-05
Est. Completion 2012-03
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT01350921

The ClinicalTrials.gov registry entry for NCT01350921 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Ticagrelor is the first listed.

NCT01350921 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01350921 about?

NCT01350921 is a clinical study titled "Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers". Study evaluates the drug-drug interaction between Ticagrelor and Venlafaxine when taken together in healthy volunteers

What is the current status of trial NCT01350921?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-05. Estimated completion is 2012-03.

What interventions are being tested in trial NCT01350921?

The interventions under investigation include: Ticagrelor (DRUG), Venlaflaxin (DRUG).

Who is sponsoring clinical trial NCT01350921?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.